STOCK TITAN

BIOLASE to Highlight Progress and Recent Achievements at the Colliers & Co. Institutional Investor Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

BIOLASE, Inc. (NASDAQ: BIOL) will present an overview of the company and its recent progress at the Colliers & Co. Institutional Investor Conference on September 10, 2020. Executives Todd Norbe and John Beaver will engage in virtual meetings with institutional investors. Norbe expressed optimism regarding BIOLASE's positioning for growth post-COVID-19, citing enthusiasm for recent study results on Waterlase-assisted treatment of periodontitis. BIOLASE has sold over 41,200 dental laser systems globally, leveraging 261 patented and 52 patent-pending technologies to improve dental procedures.

Positive
  • Successful positioning of BIOLASE for post-pandemic growth.
  • Enthusiasm around recent study results for Waterlase-assisted treatments.
  • Strong global sales record with over 41,200 laser systems sold.
Negative
  • None.

FOOTHILL RANCH, Calif., Sept. 3, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements at the Colliers & Co. Institutional Investor Conference on Thursday, September 10, 2020.  The conference will feature virtual one-on-one meetings with the BIOLASE' executives and institutional investors are invited to request meeting times at tkehrli@evcgroup.com or through their Colliers representative. 

"We worked diligently to position BIOLASE for future growth and success, and I believe the results of our hard work was beginning to demonstrate success prior to the COVID-19 pandemic," commented Mr. Norbe.  "While the pandemic has caused widespread business disruption, including the dental market, I want to reaffirm that BIOLASE remains well-positioned for the opportunity ahead as general practitioners and DSOs are eagerly looking for ways to provide safe services for their patients as they reopen their offices.  Also, the recently published results of the landmark study performed by The McGuire Institute, together with the patient reported outcomes of Waterlase-assisted treatment of periodontitis, has generated enthusiasm within BIOLASE and the dental community and we are excited to share our story with investors."

About BIOLASE, Inc.

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals.  BIOLASE's proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times.  BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.  BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world.  Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-to-highlight-progress-and-recent-achievements-at-the-colliers--co-institutional-investor-conference-301123704.html

SOURCE BIOLASE, Inc.

FAQ

What will BIOLASE present at the Colliers & Co. Conference on September 10, 2020?

BIOLASE will provide an overview of the company and its recent progress at the Colliers & Co. Institutional Investor Conference.

Who are the executives presenting on behalf of BIOLASE at the conference?

Todd Norbe, President and CEO, and John Beaver, COO and CFO, will present at the conference.

What are the recent achievements highlighted by BIOLASE?

BIOLASE highlighted its positioning for growth post-COVID-19 and positive outcomes from a recent study on Waterlase-assisted treatment.

How many dental laser systems has BIOLASE sold worldwide?

BIOLASE has sold over 41,200 dental laser systems in over 80 countries.

BIOLASE INC

OTC:BIOL

BIOL Rankings

BIOL Latest News

BIOL Stock Data

2.39M
33.40M
0.3%
6.56%
5%
Medical Devices
Dental Equipment & Supplies
Link
United States of America
FOOTHILL RANCH